This study showed that drug M2000 as a novel NSAID with immunosuppressive property is able strongly to inhibit the activity of COX-1/COX-2 enzymes, with suppressing the gene expression of COX-2 specifically. Therefore, based on gene expression findings this drug might be categorized and introduced as a novel NSAID with selective COX-2 inhibitory effect.
This study revealed that G2013, as a novel NSAID with the immunomodulatory property, is able to reduce the gene expression and activity of COX-1/COX-2 enzymes. According to the findings, this agent might be categorized and introduced as a novel NSAID for the treatment of inflammatory diseases.
This research showed that M2000 as a novel NSAID with immunosuppressive properties could modify oxidative stress through lowering expression levels of the SOD2, GST, iNOS, and MPO genes compared to the healthy expression levels, with a probable reduction of the risk of developing inflammatory diseases related to age and aging.
Introduction:
Recently, the coronavirus disease 2019 (COVID-19) infection, with a vast
spectrum of clinical and paraclinical symptoms has been a major health concern worldwide. Therapeutical management of COVID-19 includes antiviral and anti-inflammatory drugs. NSAIDs, as the second-line therapy, are often prescribed to relieve the symptoms of COVID-19. The a-L-guluronic acid
(G2013) is a non-steroidal patented (PCT/EP2017/067920) agent with immunomodulatory properties.
This study investigated the effect of G2013 on the outcome of COVID-19 in moderate to severe patients.
Methods:
The disease’s symptoms were followed up during hospitalization and for 4 weeks postdischarge in G2013 and control groups. Paraclinical indices were tested at the time of admission and
discharge. Statistical analysis was performed on clinical and paraclinical parameters and ICU admission and death rate.
Result:
The primary and secondary outcomes indicated the efficiency of G2013 on COVID-19 patients’ management. There were significant differences in the duration of improvement of fever,
coughing, fatigue/malaise. Also, a comparison of paraclinical indices at the time of admission and discharge showed significant change in prothrombin, D-dimer, and platelet. As the main findings of this
study, G2013 significantly decreased the percentage of ICU admission (control:17 patients, G2013:1
patient) and death (control: 7 cases, G2013:0).
Conclusion:
These results conclude that G2013 has sufficient potential to be considered for moderate
to severe COVID-19 patients, can significantly reduce the clinical and physical complications of this
disease, has a positive effect on modulating the coagulopathy process, and aids in saving lives.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.